Background
A health-plan beneficiary sued Fundação CESP for authorization and payment of intensity-modulated radiation therapy (IMRT), as well as compensation for moral harm. The beneficiary had experienced multiple malignancies, including melanoma, prostate cancer, and a rare, aggressive cancer in the gluteal region.
The trial court partially granted relief, confirmed its preliminary order, required Fundação CESP to fund the IMRT treatment, and awarded R$8,000 in moral damages. The state appellate court affirmed the judgment in full. After a single-justice decision declined to hear Fundação CESP’s special appeal under STJ Precedents 7 and 83, the foundation filed an internal appeal before the Fourth Panel.
The Court’s Holding
The Fourth Panel unanimously denied the internal appeal. It held that STJ Precedent 83 barred the challenge to coverage because the state court’s ruling accorded with settled STJ case law requiring health-plan operators to cover procedures forming part of cancer treatment. The court found that IMRT was included in the ANS coverage list and rejected the argument that the plan’s self-managed status or the ANS utilization guidelines justified denial.
The court explained that ANS utilization guidelines organize the provision of treatments and procedures but may not restrict essential diagnostic techniques or therapeutic alternatives, particularly where conventional treatments have been exhausted and evidence supports the prescribed therapy. It also held that STJ Precedent 7 prevented reconsideration of moral damages because doing so would require reexamining facts established below, including the improper refusal, resulting treatment delay, and heightened distress to the patient.
Key Takeaways
- A health-plan operator must cover procedures forming part of covered cancer treatment, including IMRT in this case.
- Self-managed plan status and ANS utilization guidelines did not permit the operator to restrict medically necessary oncology treatment.
- The STJ will not revisit a moral-damages determination when the requested review depends on reassessing the evidentiary record.
Why It Matters
The decision reinforces the STJ’s treatment-specific approach to oncology coverage: an insurer cannot rely on abstract disputes over the ANS list or its utilization guidelines to withhold procedures integral to cancer care. That principle applies to self-managed health plans as well as other operators.
The ruling also illustrates the procedural limits of a special appeal. Where lower courts base moral damages on case-specific findings about denial, delay, and patient distress, STJ Precedent 7 ordinarily forecloses further factual review.